Evidence map›Paper›PMID 39073567›Full record

ArticleLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2024

Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium.

Xing Li, Tianqi Ouyang, Justin M Belcher, Kavish R Patidar, Giuseppe Cullaro, Sumeet K Asrani, Hani M Wadei, Douglas A Simonetto, Kevin R Regner, Leigh A Dageforde and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Xing LiDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Tianqi OuyangDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Justin M BelcherSection of Nephrology, Department of Internal Medicine, Yale University and VA Connecticut Healthcare, New Haven, Connecticut, USA.
Kavish R PatidarSection of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Giuseppe CullaroDivision of Digestive and Liver Diseases, Department of Medicine, Columbia University, New York City, New York, USA.
Sumeet K AsraniBaylor University Medical Center, Dallas, Texas, USA.
Hani M WadeiDepartment of Transplantation, Mayo Clinic, Jacksonville, Florida, USA.
Douglas A SimonettoDivision of Gastroenterology and Transplant Hepatology, Mayo Clinic, Rochester, Rochester, Minnesota, USA.
Kevin R RegnerDivision of Nephrology at the Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Leigh A DagefordeDepartment of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA.
Eric M PrzybyszewskiDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Robert M WilechanskyDivision of Gastroenterology and Hepatology, Oregon Health and Science University, Portland, Oregon, USA.
Pratima SharmaDepartment of Gastroenterology and Transplant Hepatology, University of Michigan Health, Ann Arbor, Michigan, USA.
Nneka N UfereDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andres Duarte-RojoDivision of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, Illinois, USA.
Nabeel A WahidDivision of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, Illinois, USA.
Eric S OrmanDivision of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana, USA.
Shelsea A St HillienDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jevon E RobinsonDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Raymond T ChungDivision of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andrew S AllegrettiDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
I on behalf of the HRS-HARMONY research collaborative

Funding

Personalizing Therapies for Acute Kidney Injury in CirrhosisK23DK128567 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Andrew S Allegretti · 2022 to 2026
$982k
Application of Novel Biomarkers of Renal Health in Cirrhosis Patients to Stratify Risk of Acute Kidney Injury Occurrence and ReversibilityK23DK131278 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Giuseppe Cullaro · 2022 to 2026
$812k
Development and Testing of an Integrated Care Coordination Intervention for Alcohol Use Disorder Recovery after Liver TransplantationK23AA031068 · NIAAA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Leigh Anne Dageforde · 2023 to 2026
$749k
NIAAA NIH HHS K23 AA031068NIDDK NIH HHS K23 DK128567NIDDK NIH HHS K23 DK131278
6 · The paper itself

Abstract

Acute kidney injury (AKI) frequently complicates the course of hospitalized patients with cirrhosis and negatively affects their prognosis. How AKI response influences the timing of liver transplantation (LT) remains unclear. We sought to assess the impact of AKI response to treatment on survival and LT rates in patients with cirrhosis awaiting LT. This was a retrospective multicenter study of cirrhosis patients waitlisted for LT and hospitalized with AKI in 2019. The exposure was AKI response versus no response during hospitalization. Outcomes were 90-day overall and transplant-free survival, and rates of LT with time to transplant. We adjusted for age, sex, race, cirrhosis etiology, site, and Model for End-Stage Liver Disease-Sodium (MELD-Na) score. Among the 317 patients in this study, 170 had an AKI response (53.6%), and 147 had no response (46.4%). Compared to nonresponders, responders had better 90-day overall survival (89.4% vs. 76.2%, adjusted subhazard ratio for mortality 0.34, p =0.001), and transplant-free survival (63.5% vs. 25.2%, aHR for probability of death or transplant 0.35, p <0.001). The LT rate was lower in responders (45.9% vs. 61.2%, adjusted subhazard ratio 0.55, p =0.005); 79% of transplants in responders occurred after discharge, at a median of 103 days, while 62% of transplants in nonresponders occurred during hospitalization, with the remainder occurring postdischarge at a median of 58 days. In patients with cirrhosis waitlisted for LT who are hospitalized with AKI, AKI response to therapy is associated with improved 90-day survival, despite a reduced LT rate and longer time to LT.

Indexed as

Acute Kidney InjuryLiver CirrhosisLiver TransplantationWaiting ListsAdultAgedEnd Stage Liver DiseaseFemaleHospitalizationHumansMaleMiddle AgedPrognosisRetrospective StudiesSeverity of Illness IndexSurvival Rate

Identifiers

PMID39073567
PMCPMC13268234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.